Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance maladie du ...

CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, ...

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales(recorded by Sanofi) increased 27% ...

OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from ...

PURE Engagement announces 2025 patient support programme award winners across major therapeutic areas: Cedar Knolls, New Jersey Thursday, October 30, 2025, 13:00 Hrs [IST] PURE En ...

OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent ...

Regeneron last presented early ... Lustig noted that one of those latter children did end up in the moderate class almost a year after treatment. The trial enrolled children of varying ages. The ...

GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.

Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type 2I/R9, the company was back at it again, this time reporting positive ...